HomeProductsBioactive CompoundsProteaseProteasomeOprozomib
Chemical structure of CAS 935888-69-0

Oprozomib

CAS No.935888-69-0
MDL No.MFCD25976563
MFC25H32N4O7S
MW532.60
InChI KeySWZXEVABPLUDIO-WSZYKNRRSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.935888-69-0
Product NameOprozomib

Biological Targets

PSMD1·PSMB2·PSMB1·PSMB5·PSMB8·

Associated Conditions

neoplasm·hepatocellular carcinoma·cancer·Waldenstrom macroglobulinemia·multiple myeloma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Molecular mechanisms of acquired proteasome inhibitor resistance.

Journal of medicinal chemistry • Vol. 55, Issue 23 • 2012
PMID: 22978849PMC: PMC3521846DOI: 10.1021/jm300434z

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 18, Issue 20 • 2012
PMID: 22929803PMC: PMC3473099DOI: 10.1158/1078-0432.CCR-12-1213

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

The Journal of pharmacology and experimental therapeutics • Vol. 341, Issue 1 • 2012
PMID: 22235146DOI: 10.1124/jpet.111.187542

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

Blood • Vol. 116, Issue 23 • 2010
PMID: 20805366PMC: PMC3321748DOI: 10.1182/blood-2010-04-276626

Documentation